Gilead Sciences Inc (GILD) 84.45 $GILD
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.39%
Comtex SmarTrend(R) - Fri Jun 10, 12:09PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.35 to a high of $85.17. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $85.65 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 84.45 (-1.32)
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
BusinessWire - Thu Jun 09, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L. Washington, Gilead's Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies 2016 Healthcare Conference in New York on Friday, June 10 at 10:30 a.m. Eastern Time.
GILD: 84.45 (-1.32)
Gilead Sciences (GILD) Breaks Through Support at $86.80
Comtex SmarTrend(R) - Thu Jun 09, 9:09AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $87.44 today and has reached the first level of support at $86.80. Analysts will be watching for a cross of the next downside pivot targets of $86.17 and $84.90.
GILD: 84.45 (-1.32)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.71 (-0.04), LMT: 240.58 (-0.09), GE: 30.04 (-0.20), F: 13.10 (-0.16), RF: 9.52 (-0.18), NKE: 55.11 (+0.17), WMT: 71.14 (+0.05), SRE: 109.27 (-0.73), PEP: 103.31 (-0.35), JLL: 119.90 (-2.40), AAWW: 46.02 (-0.80), AGR: 43.60 (+0.22), ANF: 18.75 (+0.11), BANC: 19.90 (-0.22), AJG: 48.03 (-0.33), MA: 95.21 (-1.81), CMS: 43.31 (-0.08), FEYE: 15.81 (-0.77), INGR: 122.54 (-0.51), ETH: 32.36 (-0.44), ICE: 261.29 (-1.23), AHS: 39.97 (-1.01), EGBN: 50.89 (-0.17), INOV: 17.66 (-0.81), WFC: 48.34 (-0.80), GSK: 40.93 (-1.13), HPQ: 13.50 (-0.34), ORCL: 38.74 (-0.31), DRI: 67.81 (-0.52), MSEX: 39.30 (+0.35), GILD: 84.45 (-1.32), CVS: 96.67 (-0.32), TAHO: 13.51 (-0.24), OSK: 45.56 (-1.14)
Should You Buy Gilead Sciences Inc?
Dana Blankenhorn - Amigobulls - Thu Jun 09, 2:49AM CDT
The P/E multiple is below 8 as analysts see falling sales. Do not expect a hasty or conventional move from Gilead Sciences Inc (NASDAQ:GILD).
GILD: 84.45 (-1.32)
Don’t Get Caught With These 5 Stocks Ahead of Earnings Season
ESTMZ - Wed Jun 08, 3:01PM CDT
First quarter earnings season is coming to an end with the earnings recession still deeply entrenched in the market’s memory. Almost all S&P 500 companies have reported and results have been largely disappointing. This marked the first time the...
AA: 9.49 (-0.35), GS: 149.89 (-3.28), GILD: 84.45 (-1.32), MRK: 56.81 (-0.37), CMG: 405.26 (-10.53), GPS: 18.92 (-0.39), AAPL: 98.83 (-0.82)
Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.30 (-0.31), GILD: 84.45 (-1.32), COST: 154.87 (+0.82), ULTA: 239.98 (-0.03), WDC: 46.85 (-1.32)
Post-Earnings Coverage Valeant Pharma under the Microscope
ACCESSWIRE - Wed Jun 08, 8:15AM CDT
Valeant Pharmaceuticals Slumps after cutting its Forecast
PRGO: 98.51 (-1.97), VRX: 24.14 (-1.34), GILD: 84.45 (-1.32)
Global Sickle Cell Disease Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Pfizer, Novartis, Gilead Sciences - Research and Markets
BusinessWire - Wed Jun 08, 6:15AM CDT
Research and Markets has announced the addition of the "Sickle Cell Disease Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
GILD: 84.45 (-1.32)
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
BusinessWire - Tue Jun 07, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, R&D and Chief Scientific Officer, will participate in a fireside chat at the Goldman Sachs 37th Annual Global Healthcare Conference in Ranchos Palos Verdes, CA on Wednesday, June 8 at 11:20 a.m. Pacific Time.
GILD: 84.45 (-1.32)
BetterInvesting Top 100 Performance Topped S&P Benchmark for 5 Years Ended May 31
PR Newswire - Tue Jun 07, 3:18PM CDT
At the end of May, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, gained 11.7 percent annually for the previous five years, versus annual growth of 11.5 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested). The Top 100 index's five-year annual performance has topped the S&P benchmark's results for five consecutive months.
SBUX: 54.87 (-0.71), UA: 38.38 (-0.28), AMZN: 717.91 (-9.74), SWKS: 65.55 (-2.42), GILD: 84.45 (-1.32), FB: 116.62 (-1.94), CVS: 96.67 (-0.32), AL: 28.08 (-1.06), GNTX: 15.98 (-0.30), AAPL: 98.83 (-0.82)
InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors
PR Newswire - Tue Jun 07, 8:00AM CDT
InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced the election of Norbert Bischofberger, Ph.D., to the company's board of directors. Dr. Bischofberger has spent over 25 years at Gilead Sciences, where he currently serves as the company's chief scientific officer and executive vice president of research and development.
GILD: 84.45 (-1.32)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.31% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 12:02PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $86.10 to a high of $87.38. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $87.30 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 84.45 (-1.32)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.31%
Comtex SmarTrend(R) - Mon Jun 06, 12:01PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $86.10 to a high of $87.38. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $87.30 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 84.45 (-1.32)
BetterInvesting Magazine Releases August Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Jun 03, 3:05PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced LKQ Corporation (NDQ: LKQ) as its August 2016 "Stock to Study" and Gilead Sciences, Inc. (NDQ: GILD) as its August 2016 "Undervalued Stock" for investors' informational and educational use.
GILD: 84.45 (-1.32), LKQ: 32.23 (-0.88)
California State Science Fair Announces 2016 Winners
PR Newswire - Wed Jun 01, 4:33PM CDT
Winners of the 2016 California State Science Fair were announced during ceremonies that took place May 24, 2016 at the California Science Center. This year's Fair drew 941 students from 421 schools statewide, with finalists selected by a volunteer pool of 356 scientists and engineers from private industry and higher education. Students took home a combined total of nearly $60,000 in cash prizes.
GILD: 84.45 (-1.32), NOC: 217.36 (-1.22)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)
Pre-Market Technical Breakdown Highlights on Biotech Stocks
ACCESSWIRE - Wed Jun 01, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 1, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Gilead Sciences, Baxalta, MannKind, and Sarepta Therapeutics.
GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), BXLT: 46.02 (-0.18), MNKD: 1.01 (-0.02)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.39%
Comtex SmarTrend(R) - Fri Jun 10, 12:09PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.35 to a high of $85.17. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $85.65 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 84.45 (-1.32)
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
BusinessWire - Thu Jun 09, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L. Washington, Gilead's Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies 2016 Healthcare Conference in New York on Friday, June 10 at 10:30 a.m. Eastern Time.
GILD: 84.45 (-1.32)
Gilead Sciences (GILD) Breaks Through Support at $86.80
Comtex SmarTrend(R) - Thu Jun 09, 9:09AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $87.44 today and has reached the first level of support at $86.80. Analysts will be watching for a cross of the next downside pivot targets of $86.17 and $84.90.
GILD: 84.45 (-1.32)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.71 (-0.04), LMT: 240.58 (-0.09), GE: 30.04 (-0.20), F: 13.10 (-0.16), RF: 9.52 (-0.18), NKE: 55.11 (+0.17), WMT: 71.14 (+0.05), SRE: 109.27 (-0.73), PEP: 103.31 (-0.35), JLL: 119.90 (-2.40), AAWW: 46.02 (-0.80), AGR: 43.60 (+0.22), ANF: 18.75 (+0.11), BANC: 19.90 (-0.22), AJG: 48.03 (-0.33), MA: 95.21 (-1.81), CMS: 43.31 (-0.08), FEYE: 15.81 (-0.77), INGR: 122.54 (-0.51), ETH: 32.36 (-0.44), ICE: 261.29 (-1.23), AHS: 39.97 (-1.01), EGBN: 50.89 (-0.17), INOV: 17.66 (-0.81), WFC: 48.34 (-0.80), GSK: 40.93 (-1.13), HPQ: 13.50 (-0.34), ORCL: 38.74 (-0.31), DRI: 67.81 (-0.52), MSEX: 39.30 (+0.35), GILD: 84.45 (-1.32), CVS: 96.67 (-0.32), TAHO: 13.51 (-0.24), OSK: 45.56 (-1.14)
Should You Buy Gilead Sciences Inc?
Dana Blankenhorn - Amigobulls - Thu Jun 09, 2:49AM CDT
The P/E multiple is below 8 as analysts see falling sales. Do not expect a hasty or conventional move from Gilead Sciences Inc (NASDAQ:GILD).
GILD: 84.45 (-1.32)
Don’t Get Caught With These 5 Stocks Ahead of Earnings Season
ESTMZ - Wed Jun 08, 3:01PM CDT
First quarter earnings season is coming to an end with the earnings recession still deeply entrenched in the market’s memory. Almost all S&P 500 companies have reported and results have been largely disappointing. This marked the first time the...
AA: 9.49 (-0.35), GS: 149.89 (-3.28), GILD: 84.45 (-1.32), MRK: 56.81 (-0.37), CMG: 405.26 (-10.53), GPS: 18.92 (-0.39), AAPL: 98.83 (-0.82)
Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.30 (-0.31), GILD: 84.45 (-1.32), COST: 154.87 (+0.82), ULTA: 239.98 (-0.03), WDC: 46.85 (-1.32)
Post-Earnings Coverage Valeant Pharma under the Microscope
ACCESSWIRE - Wed Jun 08, 8:15AM CDT
Valeant Pharmaceuticals Slumps after cutting its Forecast
PRGO: 98.51 (-1.97), VRX: 24.14 (-1.34), GILD: 84.45 (-1.32)
Global Sickle Cell Disease Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Pfizer, Novartis, Gilead Sciences - Research and Markets
BusinessWire - Wed Jun 08, 6:15AM CDT
Research and Markets has announced the addition of the "Sickle Cell Disease Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
GILD: 84.45 (-1.32)
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
BusinessWire - Tue Jun 07, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, R&D and Chief Scientific Officer, will participate in a fireside chat at the Goldman Sachs 37th Annual Global Healthcare Conference in Ranchos Palos Verdes, CA on Wednesday, June 8 at 11:20 a.m. Pacific Time.
GILD: 84.45 (-1.32)
BetterInvesting Top 100 Performance Topped S&P Benchmark for 5 Years Ended May 31
PR Newswire - Tue Jun 07, 3:18PM CDT
At the end of May, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, gained 11.7 percent annually for the previous five years, versus annual growth of 11.5 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested). The Top 100 index's five-year annual performance has topped the S&P benchmark's results for five consecutive months.
SBUX: 54.87 (-0.71), UA: 38.38 (-0.28), AMZN: 717.91 (-9.74), SWKS: 65.55 (-2.42), GILD: 84.45 (-1.32), FB: 116.62 (-1.94), CVS: 96.67 (-0.32), AL: 28.08 (-1.06), GNTX: 15.98 (-0.30), AAPL: 98.83 (-0.82)
InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors
PR Newswire - Tue Jun 07, 8:00AM CDT
InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced the election of Norbert Bischofberger, Ph.D., to the company's board of directors. Dr. Bischofberger has spent over 25 years at Gilead Sciences, where he currently serves as the company's chief scientific officer and executive vice president of research and development.
GILD: 84.45 (-1.32)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.31% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 12:02PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $86.10 to a high of $87.38. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $87.30 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 84.45 (-1.32)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.31%
Comtex SmarTrend(R) - Mon Jun 06, 12:01PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $86.10 to a high of $87.38. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $87.30 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 84.45 (-1.32)
BetterInvesting Magazine Releases August Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Jun 03, 3:05PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced LKQ Corporation (NDQ: LKQ) as its August 2016 "Stock to Study" and Gilead Sciences, Inc. (NDQ: GILD) as its August 2016 "Undervalued Stock" for investors' informational and educational use.
GILD: 84.45 (-1.32), LKQ: 32.23 (-0.88)
California State Science Fair Announces 2016 Winners
PR Newswire - Wed Jun 01, 4:33PM CDT
Winners of the 2016 California State Science Fair were announced during ceremonies that took place May 24, 2016 at the California Science Center. This year's Fair drew 941 students from 421 schools statewide, with finalists selected by a volunteer pool of 356 scientists and engineers from private industry and higher education. Students took home a combined total of nearly $60,000 in cash prizes.
GILD: 84.45 (-1.32), NOC: 217.36 (-1.22)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)
Pre-Market Technical Breakdown Highlights on Biotech Stocks
ACCESSWIRE - Wed Jun 01, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 1, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Gilead Sciences, Baxalta, MannKind, and Sarepta Therapeutics.
GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), BXLT: 46.02 (-0.18), MNKD: 1.01 (-0.02)
